Over the past years, antibody-drug conjugate (ADC) as a promising and effective therapeutic agent has been developed widely for a variety of cancer therapies. ADCs possess unique advantages such as the specificity and potent antitumor activity compared with other traditional therapeutic options.
Creative Biolabs is a global leader in the field of antibody development and bio-conjugation, and we offer custom ADCs development services against mesothelin-expressing tumours. With extensive experience in linker-payload synthesis, antibody production and conjugation technology, Creative Biolabs has constructed mature system for ADCs design and construction. Our experienced scientists also provide an extensive range of ADCs related products for ADCs preparation.
Mesothelin (MSLN) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein and is a type of tumour differentiation antigen. Normally, it exists in the mesothelial cells lining the pleura, peritoneum and pericardium. However, the abnormal expression of the protein can cause many cancers including malignant mesothelioma (MM), pancreatic, ovarian and lung adenocarcinoma. Mesothelin is highly expressed in all epithelial malignant mesothelioma. In pancreatic cancer (PC), mesothelin is expressed in all pancreatic adenocarcinomas but absent in normal pancreas, islet cell tumors of the pancreas and in chronic pancreatitis. Mesothelin is overexpressed in most serious ovarian cancers. During lung cancer, mesothelin is present in about half the patients with lung adenocarcinoma. Therefore, mesothelin is a useful marker during the targeted immunotherapy for mesothelin-expressing tumours due to its limited expression in normal tissues and high expression in cancers.
Fig.1 Mesothelin is expressed in different human tumours. (Pastan, 2014)
Mesothelin is highly expressed in many tumours and it has become an attractive target for a variety of therapeutic options. These targeted immunotherapies include the monoclonal antibodies, ADCs, anti-MSLN immunogenic toxin, CAR T-cell therapy and so on.
Fig.2 MSLN-targeted therapy strategies. (Lv, 2019)
Creative Biolabs has many years of experience in the fields of antibody production and bio-conjugation, we now offer a full range of ADCs development services against the mesothelin-expressing tumours. Creative Biolabs is confident in speeding your novel ADCs drug discovery project and achieving ideal development goals with the most competitive price. For more information, please feel free to contact us.
Reference
For Research Use Only. NOT FOR CLINICAL USE.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Contact us